Seno Medical Instruments, Inc.
RELATED CONTENT
Seno Medical Instruments Inc. announced that the use of the Seno Imagio breast imaging system and the associated predictive model appear to have the potential to significantly improve physicians' ability to accurately rule out breast cancer compared to traditional ultrasound alone.
November 11, 2014 
Seno Medical Instruments Inc. announced it has completed active enrollment of subjects in its U.S.-based PIONEER Pivotal Study of Imagio.
October 07, 2014 Seno Medical Instruments Inc. presented two analyses of outcomes from a U.S. Feasibility Study of its investigational Imagio breast-imaging device at the annual meeting of the European Congress of Radiology 2014.
March 26, 2014 Seno Medical Instruments, Inc., the company pioneering opto-acoustic imaging as a tool to improve the diagnosis of cancer, announced today that the first 100 patients have been enrolled into its Pivotal Study of Imagio, a new opto-acoustic imaging system that may help women with benign breast masses avoid negative, invasive biopsies.
January 22, 2014 
Seno Medical Instruments, Inc., the company pioneering opto-acoustic imaging as a tool to improve the process of diagnosing breast cancer, today announced preliminary information from a feasibility study of its Imagio breast imaging device. Results from the feasibility study suggest that information from Imagio, beyond that available from traditional breast ultrasound, may be helpful in assisting physicians in their decisions whether to recommend biopsies for women with suspicious breast masses. The data were presented at the annual meeting of the Radiological Society of America (RSNA).
December 20, 2013 March 12, 2009 - Frost & Sullivan gave SENO Medical Instruments the 2009 North American Medical Imaging Emerging Company of the Year Award for pioneering the pre-clinical opto-acoustic imaging technology used to treat cancer.
March 12, 2009